Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the bioequivalence of the newly formulated Tylenol tablet (acetaminophen 650 mg) with respect to the Tylenol 8 Hour (H) Extended Release (ER) tablet (acetaminophen 650 mg) in healthy participants under fasting conditions.
Interventions
DRUGAcetaminophen
Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Sponsors
Janssen Korea, Ltd., Korea
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents * Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel including liver enzymes, other specific tests, hematology, urinalysis or breathing alcohol test are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator * Blood pressure (after the participant is sitting for 5 minutes) between 90 and 140 millimeters of Mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic * Have no history of psychiatric disorder within the 5 years prior to the screening * Have no history of gastrointestinal resection that may affect drug absorption
Exclusion criteria
* History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency (creatinine clearance below 60 milliliter per minute \[mL/min\]), thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results * Clinically significant abnormal physical examination, vital signs, or 12 lead ECG at screening as deemed appropriate by the investigator * Known allergies, hypersensitivity, or intolerance to acetaminophen or its excipients * History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence) * Taken any disallowed therapies as noted in local prescribing information, concomitant therapy before the planned first dose of study drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Analyte Concentration (Cmax) | Up to 24 hours post-dose | Cmax is the maximum observed analyte concentration. |
| Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUC [0-last]) | Up to 24 hours post-dose | AUC (0-last) is the area under the concentration-time curve from time 0 to time of the last measurable concentration (non-below quantitation limit). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Reach the Maximum Observed Analyte Concentration (Tmax) | Up to 24 hours post-dose | Tmax is the time to reach the maximum observed analyte concentration. |
| Time to Last Measurable Plasma Concentration (T [last]) | Up to 24 hours post-dose | Tlast is the time to last measurable plasma concentration. |
| Area Under the Concentration-time Curve From Time 0 to Infinite Time (AUC[0-infinity]) | Up to 24 hours post-dose | AUC(0-infinity) is the area under the concentration-time curve from time 0 to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z). |
| Elimination Half-Life (t 1/2) | Up to 24 hours post-dose | t1/2 is defined as apparent is associated terminal elimination half-life associated with the terminal slope (lambda \[z\]) of the semilogarithmic drug concentration-time curve, calculated as: 0.693/lambda(z). |
| Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability | Up to 41 days | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
| Elimination Rate Constant (Lambda [z]) | Up to 24 hours post-dose | Lambda (z) is the apparent terminal elimination rate constant determined by linear regression using the terminal log-linear phase of the log transformed concentration-time curve. |
| Percentage of Area Under the Concentration-time Curve Extrapolated from Last Measurable Concentration to Infinite Time (Extrapolated %AUCinfinity) | Up to 24 hours post-dose | Percentage of area under the concentration-time curve extrapolated from last measurable concentration to infinite time (extrapolated %AUCinfinity) is calculated using formula: (AUC \[0-infinity\] minus AUC \[0-last\]/AUC \[0-infinity\])\*100. |
Countries
South Korea
Outcome results
None listed